Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and tolerability of the COVID ‐19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors

7 Sept 2021

Abstract excerpt

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to Kawasaki Disease and Coronary Complications
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34492161
DOI: 10.1002/art.41977

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and tolerability of the COVID ‐19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitorsPMID 34492161Read ↗

Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with kidney diseasesSemantic proximity Read ↗

New onset rheumatoid arthritis with refractory hyper-eosinophilia associated with inactivated COVID-19 vaccineSemantic proximity Read ↗

Knee Arthritis After COVID-19 Vaccination: A Seven-Cases SeriesSemantic proximity Read ↗

COVID-19 in patients with rheumatological diseases treated with anti-TNFSemantic proximity Read ↗

COVID-19 in patients with juvenile idiopathic arthritis: frequency and severitySemantic proximity Read ↗

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal diseaseSemantic proximity Read ↗

MRNA Vaccines and the Potential Risk of Connective Tissue DiseasesSemantic proximity Read ↗

New advances in juvenile idiopathic arthritis.Semantic proximity Read ↗

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study SaferSemantic proximity Read ↗

Advances from clinical trials in juvenile idiopathic arthritisSemantic proximity Read ↗

Current Medical Treatments for Juvenile Idiopathic ArthritisSemantic proximity Read ↗

Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 casesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.